Gut bacteria and lung cancer treatment side effects study
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread.
- You are 18 years or older.
- You can receive one of these treatments: a PD-1 or PD-L1 inhibitor (like pembrolizumab, nivolumab, atezolizumab, or durvalumab) alone or with chemotherapy, or a tyrosine kinase inhibitor (targeted therapy).
- You are willing to provide samples (like stool or blood) for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.